Clinical Trial Update: A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TMC435 in genotype 1 hepatitis C patients who relapsed after interferon-based therapy has completed, with results posted in February …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2014-02-04